-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-02-21
AULSF:OTC-AULSF (USD)
COMMON STOCK | Medical Devices |
Last Closing
USD 0.07Change
0.00 (0.00)%Market Cap
USD 17.01BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Values as of: 2025-02-21
COMMON STOCK | Medical Devices |
Last Closing
USD 0.07Change
0.00 (0.00)%Market Cap
USD 17.01BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Austar Lifesciences Limited, an investment holding company, engages in the provision of integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. The company operates through Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; GMP Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment segments. It also offers clean utility and bioprocess equipment, clean room, automation control and monitor system; bioprocess equipment consumables, and laboratory solutions. In addition, the company provides pharmaceutical process contamination control; packaging and aseptic containment; biosafety lab animal equipment, and consumables, as well as offers powder and solid equipment; freeze-dryer, sterile filling and visual inspection equipment. Further, it offers project management and process engineering; engineering design and consulting services; operation and maintenance of facility management systems. Additionally, the company provides lifecycle digital solutions and professional consulting services. Austar Lifesciences Limited was founded in 1991 and is headquartered in Shanghai, China.
Company Website : https://www.austar.com.hk
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
SEMHF | Siemens Healthineers AG |
N/A |
USD 67.08B |
SMMNY | Siemens Healthineers AG ADR |
+0.14 (+0.49%) |
USD 66.51B |
RYLPF | Koninklijke Philips N.V |
+1.04 (+4.19%) |
USD 25.99B |
SONVF | Sonova Holding AG |
-4.98 (-1.48%) |
USD 20.26B |
OCPNF | Olympus Corporation |
N/A |
USD 17.48B |
SSMXF | Sysmex Corporation |
N/A |
USD 11.60B |
SNNUF | Smith & Nephew plc |
N/A |
USD 11.22B |
WILLF | Demant A/S |
N/A |
USD 9.04B |
GNGBF | Getinge AB |
N/A |
USD 5.34B |
AMBBY | Ambu A/S |
N/A |
USD 4.96B |
N/A
Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 1,300.00% | 99% | N/A | 99% | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 1,300.00% | 99% | N/A | 99% | N/A | ||
Trailing 12 Months | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | N/A | N/A | N/A | N/A | N/A | ||
Risk Adjusted Return | N/A | N/A | N/A | N/A | N/A | ||
Market Capitalization | 17.01B | 95% | A | 94% | A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
The company had negative total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector